human leukocyte antigens , HLA (Abkürzung)

The full haplotype is (for relative distances see Human leukocyte antigens:

The 23-year-old Ingrid's human leukocyte antigens, which are the components in blood that indicate marrow compatibility, are not suitable.

The key to a good match lies in a group of proteins attached to all white blood cells called human leukocyte antigens, or HLA.

In addition, African Americans may have higher serum levels of human leukocyte antigens (HLA).

Human body odor has been associated with the human leukocyte antigens (HLA) genomic region.

Bone marrow specialists try to match donor and patient for six tissue factors called HLA, human leukocyte antigens.

People who need bone marrow transplants must find donors whose matching human leukocyte antigens, substances on the surface of their white blood cells, match their own.

Thus they are known as human leukocyte antigens, or HLA antigens, and they vary widely among people.

A wide range of host antigens can initiate graft-versus-host-disease, among them the human leukocyte antigens (HLAs).

H-2, the Major Histocompatibility Complex of the mouse (equivalent of the Human Leukocyte Antigens)

Bg (Bennett-Goodspeed): These are actually Human Leukocyte Antigens that cause confusing results on serological tests of erythrocytes.

An autosomal recessive disorder of iron metabolism associated with a gene tightly linked to the A locus of the human leukocyte antigens (HLA).

Their main activity is antigen presentation, they express Factor XIIIa, CD1c and Class II Human leukocyte antigens.

In humans, these antigens were first identified on a type of white blood cell (leukocyte) and were therefore named human leukocyte antigens (HLA antigens).

These immune markers are also known as major histocompatibility (MHC) antigens or more specifically in humans as human leukocyte antigens (HLA)).

The proposed mechanism of TRALI involves antibodies from donor blood components (predominantly plasma) that are directed against human leukocyte antigens (HLA).

HLA (human leukocyte antigens) were originally defined as cell surface antigens that mediate graft-versus-host disease, which resulted in the rejection of tissue transplants in HLA-mismatched donors.

HLA-A are a group of human leukocyte antigens (HLA) that are encoded by the HLA-A locus on human chromosome 6p.

In 1964, Terasaki developed the microcytotoxicity test, a tissue-typing test for organ transplant donors and recipients that required only 1 microliter each of antisera used to identify human leukocyte antigens (HLA).

To limit the risks of transplanted stem cell rejection or of severe graft-versus-host disease in allogeneic HSCT, the donor should preferably have the same human leukocyte antigens (HLA) as the recipient.

Earlier papers claimed that increased sharing of human leukocyte antigens, as well as of deleterious recessive genes expressed during pregnancy, may lead to lower rates of conception and higher rates of miscarriage in consanguineous couples.

In an ideal case, as many of the human leukocyte antigens as possible would also match between the donor and the recipient, but the desire to find a highly compatible donor organ must be balanced against the patient's immediacy of need.

A more reliable way to ascertain parenthood is via DNA analysis (known as genetic fingerprinting of individuals, although older methods have included ABO blood group typing, analysis of various other proteins and enzymes, or using human leukocyte antigens.